



Agenus to Participate at BTIG Biotechnology Conference

August 2, 2022

LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- [Agenus](#) (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference. Agenus will participate virtually and host one-on-one meetings with investors following its second quarter 2022 corporate update on the morning of August 9.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle [@agenus_bio](#). Information that may be important to investors will be routinely posted on our website and Twitter.

Contact

Ethan Lovell
Chief Corporate Affairs & Communications Officer
339-927-1763
ethan.lovell@agenusbio.com